8-K: Butterfly Network Reports Strong Q1 2026 Results

Butterfly Network announces first quarter 2026 financial results, exceeding revenue expectations with 25% year-over-year growth and improved gross margins.

Summary

• Butterfly Network reported first quarter 2026 revenue of $26.5 million, a 25% increase year-over-year.
• Gross margin improved to 68.9% from 63.0% in the prior year period.
• Adjusted EBITDA loss narrowed to $6.1 million from $9.1 million in Q1 2025.
• Net loss for the quarter was $12.7 million, an improvement from $14.0 million in the prior year.
• The company reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million and Adjusted EBITDA loss of $21 million to $25 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved margins, and successful product development milestones, indicating solid execution and a promising outlook.

Positives

• Revenue grew 25% year-over-year to $26.5 million.
• Gross margin increased to 68.9% from 63.0% in Q1 2025.
• Adjusted EBITDA loss improved by 32% year-over-year to ($6.1 million).
• Net loss decreased to $12.7 million from $14.0 million in the prior year.
• FDA clearance received for Gestational Age AI Tool.
• Two new partners added to the Butterfly Garden Ecosystem, bringing the total to 30.
• First enterprise deal closed for Compass AI and significant growth in the software pipeline.
• Meaningful development progress made with Butterfly Embedded partners, signing the ninth company.

Negatives

• Operating expenses increased slightly to $32.2 million from $31.8 million in the prior year, largely due to increased headcount and professional services costs.
• The company continues to report an Adjusted EBITDA loss, although it has narrowed.

Risks

• The company faces competition from other companies with greater financial and marketing resources.
• Ability to obtain and maintain regulatory approval for products and any related restrictions.
• Potential challenges in identifying, in-licensing, or acquiring additional technology.
• Reliance on existing license, manufacturing, supply, and distribution agreements.
• Uncertainty regarding the success, cost, and timing of out-licensing intellectual property.
• Changes in applicable laws or regulations could impact the business.
• The size and growth potential of markets and the ability to serve them.
• Pricing of products and services, and reimbursement for medical procedures.

Future Outlook

The company reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million (20%-24% growth) and Adjusted EBITDA loss guidance of $21 million to $25 million. For the second quarter of 2026, revenue is projected to be between $27 million and $31 million (approximately 24% year-over-year growth at the midpoint), with an Adjusted EBITDA loss of $6 million to $8 million.

Management Comments

• "Butterfly opened the year with another strong quarter, coming in above consensus with 25% revenue growth and continued gross margin improvement. We are executing with discipline while continuing to invest in the vast opportunity ahead."
• "Our business is starting to come together around three growth engines. Point-of-care ultrasound is scaling globally. Home & Community Care is extending that capability into the patient environment. And Butterfly Embedded is expanding our technology beyond medical ultrasound into new modalities. These are not separate opportunities. They are all part of the same Butterfly platform, a single system that is beginning to work together and compound over time. We are still early, but the direction is clear, and we are building with focus and discipline to drive long-term growth."

Industry Context

StockSavvy.ai notes that Butterfly Network's performance in Q1 2026, with strong revenue growth and improving margins, aligns with a trend of increasing adoption for point-of-care ultrasound devices and AI-driven healthcare solutions. The company's multi-pronged growth strategy, encompassing embedded technology and home care, reflects broader industry shifts towards accessible and integrated medical technology.

Comparison to Industry Standards

• The 25% year-over-year revenue growth for Q1 2026 is a strong indicator in the medical device sector, particularly for companies focused on innovative imaging technology.
• The improvement in gross margin to 68.9% suggests efficient operations and a favorable product/licensing mix, which is competitive within the specialized ultrasound market.
• The narrowing of the Adjusted EBITDA loss indicates progress towards profitability, a key metric investors watch in growth-stage medical technology companies.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved margins, and reaffirmed guidance, suggesting potential for increased shareholder value.
• Employees: Continued investment in internal capabilities and headcount to support revenue growth may lead to a dynamic work environment.
• Customers: Access to new AI tools (Gestational Age AI Tool) and expanding ecosystem partners can enhance product utility and value.
• Partners: Continued progress with Butterfly Embedded and Garden Ecosystem partners indicates ongoing collaboration and potential for mutual growth.

Next Steps

• Initiate rollout of blind-sweep AI tool for fetal age estimation.
• Continue to progress toward additional commercial-ready applications within the Butterfly Garden Ecosystem.
• Advance entry into new global markets, including Brazil.
• Progress toward the first commercial agreement for Home & Community Care, with initial statewide deployment expected in Q3 2026.
• Continue development of the Apollo Platform, a next-generation semiconductor architecture.

Key Dates

Recommendation

The company demonstrated strong Q1 performance with revenue exceeding expectations and improved margins. However, it continues to operate at a net loss and with an adjusted EBITDA loss. While guidance was reaffirmed, the path to profitability requires continued execution and market adoption. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained growth and a clear trajectory towards profitability.

Keywords

Butterfly Network, 8-K, Q1 2026 Results, Medical Imaging, Ultrasound, Revenue Growth, Adjusted EBITDA, FDA Clearance